1. Paul Maguire Enterprise Ireland Biotechnology Commercialisation in Ireland - Looking to the Future Federal Lab Consortium (FLC) / Mid-Atlantic Region (MAR) Regional Meeting - September 20 th, 2006 Cumberland, Maryland

2. “To accelerate the development of world-class Irish companies to achieve strong positions in global markets resulting in increased national and regional prosperity” 12 Offices in Ireland 34 Offices Overseas incl. 5 in the USA ENTERPRISE IRELAND’S KEY ROLE

3. EI’s US Office Network South America Canada physical office location 4 Employees 16 Employees 2 Employees 3 Employees 1 Employees

4. “Over eight years Ireland has changed dramatically. With changing times and a great deal of success new challenges and new opportunities have arisen.  Ireland today has:  The lowest level of unemployment in the EU  The second lowest national debt  The second highest minimum wage  The highest investment in the EU on infrastructure  The fastest growth of all OECD countries in spending per capita on health  The most generous tax and welfare system in the world for single income families on the average industrial wage.” Introduction to the Third Government Progress Report, July 2005

5. Irelands GDP per Capita OECD

6. R&D Expenditure 1.2 Gross domestic expenditure on R&D As a percentage of GDP, 2004 2.7

7. Life Science investment 2000-04 Investment in R&D Base: €1.3 billion invested in R&D- €645m SFI; €605m HEA.

8. National Centres National Centre for Biomedical Engineering Science NUIG The Bioscience Research Institute University College Cork Conway Institute UCD The Institute of Immunology, located in the Bioscience Building, NUI Maynooth The Trinity Centre for BioEngineering (TCBE)

9. Life-science Companies 17% Diagnostics 20% Drug Discovery and Development 17% Pharmaceuticals and Chemicals 20% Medical Devices 26% Services and Support Approx. 70 Indigenous Companies Also- Food industry investing heavily in R&D for functional foods

10. Diagnostic Agri-Food Pharmaceutical Service Bio-Environmental Services Pharmaceutical/Vaccine BELFAST DUBLIN CORK GALWAY Clusters of Irish Biotech Companies

11. Government Strategy “High levels of investment in research and innovation are essential in order to become a competitive and dynamic knowledge-based economy.” http://www.entemp.ie/publications/science/2006/sciencestrategy.pdf

12. “Over the life of this Strategy we aim to see a doubling of postgraduate researchers, with significant numbers of these going on to take up employment in the enterprise sector. We also aim to ensure more effective commercialisation of the ideas and know-how being generated in our universities and public research institutions, and to forge new partnerships between these institutions and enterprise.” Bertie Ahern T.D. Taoiseach Prime Minister of Ireland

13. Focus of Strategy  World Class Research  Capturing, Protecting and Commercialising Ideas and Know-how  Research and Development for Enterprise, Innovation and Growth  Science Education and Society  Research in the Public Sector  All-Island and International STI  Implementation “The creation, exploitation and commercialisation of research are critical if Ireland is to overcome competitive threats and sustain its economic momentum.”

14. Technology Transfer “Transfer of knowledge and technology from higher education institutes into the marketplace is recognised as being of crucial importance in the establishment of a strong research environment and a knowledge-based economy.”

15. EI-Bio Supports for Biotech. EI Bio is building the biotechnology sector through the strategic commercialisation of research in Ireland. 2 approaches to commercializing research:  Funding mechanisms to provide financial support for the development of these technologies. - support all levels of technology development from proof of concept to commercialisation and beyond.  Commercialization support to help the researcher develop the technology within a commercial context. - On-campus personnel to support all aspects of IP identification, protection and exploitation.

16. Intellectual Property National Code of Practice for Managing Intellectual Property from Publicly Funded Research- 2004 Research Institute owns the IP National Code of Practice for Managing Intellectual Property from Public-Private Collaborative Research- 2005 Ownership determined by intellectual and financial input and ability to exploit.

17. Institutional Technology Transfer Strengthening the Technology Transfer Function (The 3 rd Stream) Technology Transfer is the link between Research and the Market - Increased funding and support €30m over 5 years.  Integral part of institutional strategy.  Clear realistic goals based on track record.  Based on National Codes of Practice.  Offices resourced appropriately.  Central support provided by EI.

18. Technology Transfer will only occur when university and industry representatives work together for mutual gain. - Industry-led networks (€2m) Industry-informed research projects carried out by academia. - Competence Centres (€10-20m) Long term research programmes in academic centres managed by industry and academia. Industry- Academia Linkages

19. Strategic Emphasis Increased emphasis on National Approach to capability building. Overall innovation performance of the economy is not dependant on how specific institutions perform, but rather on how they interact with each other as elements of a collective system of knowledge creation and use. (OECD 1994)

20. EI Programmes Research CommunityResearch Community and Industry Industry Policy Approach To Get a Flow of Commercial Opportunities to Arise from the Research Community To Facilitate access by companies to Skills and Knowledge in the Research Community To build firms’ technological capabilities Programmes Commercialisation FundInnovation Partnerships RTI R&D Awareness Innovation Management International Programmes Industry-led networks

21. Technology Transfer Infrastructure Basic Research State Aid Investment

22. Questions….?

23. Paul Maguire SVP Market Development Enterprise Ireland Washington DC paul.maguire@enterprise-ireland.com On behalf of Paul Roben Director, Biotechnology Commercialisation Enterprise Ireland paul.roben@enterprise-ireland.com Thank You!